Medpace Holdings, Inc. (NASDAQ:MEDP) Receives Average Rating of “Hold” from Analysts

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) have earned an average rating of “Hold” from the thirteen analysts that are covering the stock, Marketbeat reports. Ten investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $349.30.

A number of brokerages recently weighed in on MEDP. Leerink Partners began coverage on shares of Medpace in a research report on Monday, March 24th. They set a “market perform” rating and a $330.00 target price for the company. Mizuho dropped their target price on shares of Medpace from $400.00 to $355.00 and set an “outperform” rating for the company in a research report on Wednesday, April 9th. Truist Financial dropped their target price on shares of Medpace from $333.00 to $300.00 and set a “hold” rating for the company in a research report on Wednesday, April 23rd. Robert W. Baird dropped their target price on shares of Medpace from $340.00 to $313.00 and set a “neutral” rating for the company in a research report on Wednesday, April 23rd. Finally, William Blair restated a “market perform” rating on shares of Medpace in a research report on Tuesday, April 22nd.

Insider Buying and Selling at Medpace

In other Medpace news, Director Fred B. Davenport, Jr. sold 1,712 shares of the stock in a transaction on Thursday, April 24th. The shares were sold at an average price of $301.82, for a total transaction of $516,715.84. Following the completion of the transaction, the director now owns 2,998 shares in the company, valued at $904,856.36. This trade represents a 36.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 20.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Medpace

Several hedge funds and other institutional investors have recently made changes to their positions in MEDP. Wilmington Savings Fund Society FSB raised its stake in shares of Medpace by 46.1% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 767 shares of the company’s stock valued at $255,000 after acquiring an additional 242 shares during the period. Empowered Funds LLC raised its stake in shares of Medpace by 32.5% in the fourth quarter. Empowered Funds LLC now owns 8,693 shares of the company’s stock valued at $2,888,000 after acquiring an additional 2,130 shares during the period. Stephens Inc. AR raised its stake in shares of Medpace by 4.9% in the fourth quarter. Stephens Inc. AR now owns 752 shares of the company’s stock valued at $250,000 after acquiring an additional 35 shares during the period. Kestra Private Wealth Services LLC raised its stake in shares of Medpace by 46.4% in the fourth quarter. Kestra Private Wealth Services LLC now owns 2,083 shares of the company’s stock valued at $692,000 after acquiring an additional 660 shares during the period. Finally, Savant Capital LLC raised its stake in shares of Medpace by 81.9% in the fourth quarter. Savant Capital LLC now owns 8,755 shares of the company’s stock valued at $2,909,000 after acquiring an additional 3,943 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $305.89 on Wednesday. The firm has a fifty day moving average price of $297.85 and a 200-day moving average price of $323.40. The stock has a market cap of $8.79 billion, a PE ratio of 24.22, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47. Medpace has a 1 year low of $250.05 and a 1 year high of $459.77.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.06 by $0.61. The firm had revenue of $558.57 million during the quarter, compared to analysts’ expectations of $528.38 million. Medpace had a net margin of 19.17% and a return on equity of 51.48%. During the same period in the prior year, the company posted $3.20 earnings per share. On average, research analysts expect that Medpace will post 12.29 EPS for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.